Potential Positive Effects using Coenzyme Q10 Supplement as Adjuvant Therapy to Gabapentin for Managing Diabetic Neuropathy
Authors:
- Rusul AbdulKareem HadiRHRusul AbdulKareem Hadi
- Isam Noori SalmanISIsam Noori Salman
Open Access
- 23 December 2022
- journal article
- research article
- Published by College of Pharmacy University of Baghdad in Iraqi Journal of Pharmaceutical Sciences
- Vol. 31 (2) , 177-183
Abstract
The most prevalent chronic complication of diabetes mellitus is diabetic neuropathy. The pathogenesis of diabetic neuropathy is exacerbated by hyperglycemia-induced oxidative stress, which causes nerves to deteriorate in a programmed manner. Many clinical trials depend on supplement in an attempt to improve neuropathy symptoms such as (pain & tingling) and patient quality of life, one of them is Coenzyme Q10 which is reported to have an anti-inflammatory and antioxidant effects, and was totally nontoxic and non-reported side effects. This study aimed to evaluate using a Coenzyme Q10 supplement as an adjuvant therapy to gabapentin to improve the clinical symptoms of diabetic neuropathy in relation to its anti-inflammatory and antioxidant effects. This open-label interventional study involved 33 diabetic neuropathy patients divided into two groups: group (1) 16 patients were given 300 mg of gabapentin once a day at evening, plus group (2) 17 patients received 300 mg of gabapentin once a day in the evening plus Coenzyme Q10 200mg once daily. Pre- and post-3 months of treatment, blood samples used to measure metabolic, anti-inflammatory and antioxidant biomarkers (fasting blood glucose, glycated hemoglobin, tumor necrosis factor-α, Iinterleukin-6 & Superoxide dismutase) , as well as the Michigan neuropathy screening instrument for assessment of clinical symptoms. After 3 months of Coenzyme Q10 use, the results showed that the group 2 produced a highly significant change in glycated hemoglobin & fasting blood glucose levels. Meanwhile, there is no significant change in glycated hemoglobin & fasting blood glucose values in patients receiving just gabapentin. Moreover, results showed highly significant differences in Michigan neuropathy screening instrument, tumor necrosis factor-α, iinterleukin-6 & superoxide dismutase between the study groups at the completion of the research. Finally, addition of Coenzyme Q10 to gabapentin for diabetic neuropathy patients result in improving the glycemic control & symptoms of the diabetic neuropathy, as well as decreasing effects of the inflammation in addition to oxidative stress after three months of treatment.Keywords
This publication has 17 references indexed in Scilit:
- Hyperglycemia and diabetes mellitus are related to vestibular organs dysfunction: truth or suggestion? A literature reviewActa Diabetologica, 2018
- Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial FunctionJournal of Diabetes Research, 2016
- Effects of coenzyme Q10supplementation on metabolic profile in diabetes: a systematic review and meta-analysisJournal of Clinical Pharmacy and Therapeutics, 2015
- Diabetic neuropathic pain development in type 2 diabetic mouse model and the prophylactic and therapeutic effects of coenzyme Q10Neurobiology of Disease, 2013
- The effect of ubiquinone in diabetic polyneuropathy: A randomized double-blind placebo-controlled studyJournal of Diabetes and its Complications, 2012
- A novel mechanism of coenzyme Q10 protects against human endothelial cells from oxidative stress-induced injury by modulating NO-related pathwaysThe Journal of Nutritional Biochemistry, 2012
- Diabetic neuropathy: cellular mechanisms as therapeutic targetsNature Reviews Neurology, 2011
- Effect of coenzyme Q10 on cutaneous healing in skin-incised miceArchives of Pharmacal Research, 2009
- Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES‐55)Diabetic Medicine, 2008
- The role of muscle spindles in ankle movement perception in human subjects with diabetic neuropathyExperimental Brain Research, 1998